Executive Summary
Today's structural heart news centers on the tricuspid valve space, where real-world comparative data from Vancouver offer the first direct look at patient profiles and outcomes between transcatheter edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR) — revealing that these are fundamentally different patient populations with sobering 12-month mortality in both groups. Meanwhile, a novel "ELASTA-T" technique from the German Heart Centre demonstrates how to rescue failed T-TEER by electrosurgically detaching clips to enable subsequent valve replacement. On the financial front, a consequential 48-hour window opens: Boston Scientific reports earnings tomorrow and Edwards Lifesciences on Wednesday, with both stocks under significant pressure and the structural heart growth narrative hanging in the balance.
For the clinical audience: this is a day to zoom out on the tricuspid transcatheter landscape. The ESC 2025 guidelines elevated T-TEER and TTVR to Class IIa based on TRILUMINATE, Tri.Fr, and TRISCEND II — but today's single-center Canadian data (n=43) remind us that real-world mortality at 12 months runs 29–34%, far exceeding the rosier trial numbers. The ELASTA-T technique, while technically ingenious, underscores an uncomfortable reality: we are building bail-out strategies for therapies whose primary efficacy is still being established. Also notable: a Japanese TAVI registry (n=1,008) delivers rare 10-year readmission data showing that both cardiac and non-cardiac readmissions after TAVI carry roughly equivalent hazard ratios for mortality — a finding that should inform how we counsel elderly patients about the full arc of post-procedural risk. And an Annals of Thoracic Surgery letter takes aim at unmeasured confounders in TAVR comparisons among younger adults, echoing persistent concerns about indication creep in lower-risk populations.
Today's Key Findings
- [NOTABLE] T-TEER vs. TTVR Comparison: First comparative data from a single Canadian center (n=43) show distinct patient phenotypes — T-TEER patients had better GLIDE scores while TTVR patients were sicker with higher TRI-scores. Twelve-month mortality was 29% (T-TEER) vs. 34% (TTVR), with 37% heart failure readmission overall. No in-hospital or 30-day deaths in the T-TEER group. Critical caveat: This is a tiny, retrospective, single-center study with no randomization — patient selection entirely explains the differences.
- [NOTABLE] ELASTA-T Technique: German Heart Centre Munich describes a standardized method for electrosurgically detaching centrally-placed tricuspid clips that obstruct subsequent TTVR deployment. Based on BASILICA/LAMPOON principles. Technically elegant but raises the question: if we need rescue strategies this early, how mature is our primary therapy?
- Post-TAVI Readmissions and Mortality (n=1,008): Japanese 10-year data show all readmission types — heart failure (HR 5.54), infection (HR 5.00), stroke (HR 5.69), and fracture (HR 4.47) — carry significantly elevated mortality risk. Fracture-related readmissions showed a secondary peak around year 2.
- Fragmented QRS as TAVI Risk Marker: In 149 patients, preprocedural fQRS independently predicted in-hospital MACE (OR 3.77). A simple, free ECG finding that could enhance risk stratification.
- Unmeasured Confounders in Young TAVR Patients: Annals of Thoracic Surgery correspondence highlights interpretational concerns in TAVR comparisons among younger adults — aligning with the broader surgical community's caution about extending TAVR below evidence-supported age thresholds.
Aortic Valve (TAVR/TAVI)
Post-TAVI Readmissions: Both Cardiac and Non-Cardiac Events Signal Mortality Risk
Naito et al. (Int J Cardiol Heart Vasc, 2026) present a retrospective analysis of 1,008 patients (mean age 85±5 years, 32% male) who underwent TAVI between 2014 and 2024 at a single Japanese center. Using time-dependent Cox models with competing risk analysis, they found that all types of hospital readmission were associated with roughly 4.5- to 5.7-fold increases in all-cause mortality: heart failure (HR 5.54), infection (HR 5.00), stroke (HR 5.69), and fracture (HR 4.47). The 10-year cumulative incidence of heart failure readmission was 38%, fracture 23%, infection 10%, and stroke 9%. Notably, most readmissions clustered in year one, but fracture showed a secondary rise around year two, and all event types increased again after year three.
Editorial note: These data are important for several reasons. First, they provide rare 10-year follow-up in an elderly TAVI cohort — a population where competing risks dominate. Second, the magnitude of non-cardiac readmission hazards (fracture HR 4.47, infection HR 5.00) is striking and comparable to heart failure readmission. This underscores that TAVI in octogenarians is not a one-time fix; the frailty trajectory continues. For shared decision-making, especially in patients near the futility boundary, these data should temper expectations. Limitations include single-center Japanese data (different healthcare system, demographics, and frailty profiles from Western cohorts) and potential survivor bias in 10-year estimates.
Fragmented QRS Predicts In-Hospital MACE After TAVI
Kurtul et al. (Am J Cardiol, 2026) retrospectively analyzed 149 TAVI patients and found that fragmented QRS (fQRS) — present in 36% — was independently associated with in-hospital MACE (48.1% vs. 18.9%, p<0.001; adjusted OR 3.77). Patients with fQRS also had higher rates of contrast-induced AKI. Low hemoglobin and smaller valve size were additional independent predictors. While the sample is small and single-center, fQRS is a free, readily available ECG marker that could be incorporated into preprocedural risk assessment. Prospective validation in larger cohorts is needed before clinical adoption.
Neosinus Thrombosis After TAVR: A Comprehensive Review
Chen et al. (JAHA, 2026) provide a systematic review of neosinus formation and its relationship to leaflet thrombosis after TAVR — a topic of increasing importance as TAVI extends to younger, lower-risk patients where valve durability is paramount. The review synthesizes evidence on anatomical remodeling, hemodynamic determinants, and thrombosis mechanisms, concluding that local hemodynamics is the dominant and potentially modifiable factor. The authors advocate for patient-specific computational modeling to optimize THV design and deployment. This connects directly to the in silico study below and to the broader Boxwell et al. (Comput Methods Programs Biomed, 2026) computational analysis showing that THV oversizing increases leaflet oscillatory shear stress and viscous shear downstream — both markers of thrombogenic risk. These findings reinforce the ESC 2025 emphasis on lifetime management planning and raise questions about whether current sizing algorithms adequately account for long-term thrombotic risk.
TAVI Efficiency Gains in Canada Without Compromising Safety
Bhatt et al. (CJC Open, 2026) report on a quality improvement initiative at a Canadian TAVI center (n=1,019 patients, 2019–2024) demonstrating significant increases in annual case volume (+0.51 cases/year) and decreases in total OR time (-10.2 minutes/year) through conscious sedation, left ventricular pacing, and hybrid closure strategies. High-case-volume days showed comparable outcomes to lower-volume days except for reduced bleeding. This is health system optimization data rather than clinical discovery, but it matters in the Canadian context where TAVI wait times can be substantial, and it provides a replicable efficiency framework.
Unmeasured Confounders in TAVR Comparisons Among Young Adults
Huang et al. (Ann Thorac Surg, 2026) contribute a correspondence highlighting interpretational pitfalls when comparing TAVR outcomes in younger patients. While the full text is not available, the title alone signals continued surgical community concern about unmeasured confounding in non-randomized TAVR studies — a theme consistent with critiques from Badhwar and Mehaffey regarding indication creep. This is particularly relevant given the ESC 2025 guideline shift recommending TAVI at age ≥70 with tricuspid AV anatomy: patients aged 65–70 sit in a contested zone where the ACC/AHA allows shared decision-making but the ESC prefers SAVR. These correspondences serve as important guardrails against over-interpretation of observational data in younger patients where SAVR durability advantages may be most consequential.
Additional Aortic Valve Items
- Apple Watch VO2max Tracking for AS Progression: Al-Saadi et al. (EHJ Case Reports, 2026) describe a 68-year-old whose Apple Watch-derived VO2max declined from 36 to 26 mL/kg/min over 3 years, prompting evaluation that revealed progression from moderate to severe AS. Post-TAVR, VO2max recovered to 41 mL/kg/min. An intriguing n=1 case that highlights the potential for consumer wearables in asymptomatic AS surveillance — but validation studies are needed before any clinical recommendation.
- TAVR in Quadricuspid Aortic Valve — Correction Notice: Khalifa et al. (Front Cardiovasc Med, 2026) published a correction to their systematic review of TAVR in quadricuspid valves. Noteworthy only as a reminder that this exceedingly rare anatomy (prevalence ~0.01%) presents unique challenges for transcatheter therapy.
- Alternative Access for TAVR: Two case reports address access challenges: Barber et al. describe an axillary conduit with passive cerebral perfusion shunt for a patient with severe aortic arch disease, and Rivera-Pedraza et al. report dual collagen-based closure devices as rescue for failed suture-mediated 14F arteriotomy closure.
- Transcatheter Closure of Ruptured Sinus of Valsalva: Shahri et al. (EHJ Case Reports, 2026) report successful percutaneous closure of a ruptured noncoronary SVA using a PDA occluder device — expanding the transcatheter toolkit for rare structural emergencies.
- Valve-in-Valve TPVR for Carcinoid Heart Disease: Antonelli et al. (EHJ Case Reports, 2026) describe Melody valve implantation in a 30-year-old with CHD and degenerated bioprosthetic pulmonic valve. Highlights the growing role of TPVR in niche high-risk populations.
Mitral Valve (MitraClip, PASCAL, TMVR)
TEER vs. Surgery in Acute Severe Primary MR: A Cardiac ICU Perspective
Lohse et al. (Arch Cardiovasc Dis, 2026) report on transcatheter edge-to-edge repair versus surgery in acute severe primary mitral regurgitation from a cardiac ICU experience. No abstract is available, but the title alone is provocative — acute severe PMR (e.g., ruptured chordae, flail leaflet) is traditionally an urgent surgical indication with excellent repair rates. Using TEER in this setting would represent a significant deviation from both ACC/AHA and ESC guidelines, which position TEER as Class IIa only for high-surgical-risk patients with suitable anatomy. Watch for the full publication details; the clinical context (cardiogenic shock, prohibitive surgical risk) will be critical for interpretation.
Tricuspid Valve (TriClip, TTVR)
T-TEER vs. TTVR: Different Patients, Different Diseases?
[NOTABLE] Jelisejevas et al. (CJC Open, 2026) provide the first direct comparison of patient profiles and outcomes between T-TEER (n=14) and TTVR (n=29) from a single Canadian center (May 2018–April 2023). Key findings:
- TTVR patients were numerically younger (76 vs. 80 years) with higher TRI-scores (6.0 vs. 4.5) and significantly higher GLIDE scores, suggesting more complex anatomy less amenable to clip-based repair
- In-hospital mortality: 7% overall; no deaths in T-TEER vs. all deaths in TTVR group
- 30-day mortality: 12% overall; 0% in T-TEER vs. all in TTVR
- 12-month mortality: 29% T-TEER vs. 34% TTVR
- Heart failure readmission at 12 months: 37% overall
- Hospital stay was significantly longer for TTVR (median 1 day, IQR 1–4 vs. 1 day, IQR 1–1)
Editorial perspective: These numbers deserve careful parsing. The 12-month all-cause mortality of 29–34% in both groups is sobering — far exceeding the event rates in TRILUMINATE (9.3% at 1 year) and TRISCEND II (~12% at 1 year). This likely reflects several factors: smaller sample, real-world patient selection beyond trial criteria, and the Canadian healthcare context where referral patterns may differ. The finding that T-TEER and TTVR patients represent different phenotypes is clinically intuitive — repair works best when anatomy cooperates (lower GLIDE scores), while replacement is reserved for anatomically challenging cases. But the 12-month mortality in both groups raises the fundamental question: are we treating these patients too late? The ESC 2025 guidelines' emphasis on avoiding referral when severe RV dysfunction and end-organ damage have already occurred is directly relevant. This study cannot tell us about optimal patient selection — it tells us about the patients we're currently selecting, and the outcomes should give us pause. The sample is far too small for any statistical comparison between groups.
ELASTA-T: A Rescue Technique for Failed T-TEER Before TTVR
Alvarez-Covarrubias et al. (EuroIntervention, 2026) from the German Heart Centre Munich describe the ELASTA-T (Electrosurgical Laceration and Stabilisation of T-TEER) technique — a standardized method for converting failed T-TEER to TTVR when centrally positioned clips obstruct valve replacement deployment. The technique borrows from BASILICA and LAMPOON principles: a modified "flying V" coronary guidewire is used to electrosurgically lacerate the leaflet tissue, detaching the most centrally placed clip, which is then mobilized toward the septal leaflet to clear space for transcatheter valve implantation.
Editorial note: This is technically impressive work, and the step-by-step standardization is valuable for the interventional community. However, it also highlights an uncomfortable reality about the current tricuspid transcatheter ecosystem. We are building rescue pathways for a therapy that received its first guideline endorsement only months ago (ESC 2025, Class IIa). The need for ELASTA-T underscores that T-TEER durability remains a concern — recurrent TR after clip therapy is not uncommon — and that our "lifetime management" planning for tricuspid interventions is still in its infancy. The technique requires bilateral femoral venous access, deflectable sheaths, microcatheters, snare-assisted rails, and preventive hemodynamic support on standby. This is not a community-hospital procedure. The question isn't whether we can do this, but whether the initial therapeutic strategy should be better optimized to reduce the need for it.
News Coverage: Real-World TTVR Data
Both Diagnostic and Interventional Cardiology and Medscape covered the previously published STS/ACC TVT Registry TTVR data (1,034 procedures, 98.4% implantation success, 3.1% 30-day mortality, 15.9% new CIED in pacemaker-naive patients). The coverage emphasizes positive outcomes, but readers should note: 30-day mortality of 3.1% in a procedure designed for symptomatic relief (not mortality reduction) establishes a meaningful safety threshold, and the 15.9% pacemaker rate is a significant morbidity signal that deserves ongoing scrutiny as volumes scale.
Surgical vs. Transcatheter Comparisons
Today's direct comparison data are limited, but two items warrant attention:
- TEER vs. Surgery in Acute PMR: The Lohse et al. cardiac ICU report (discussed above) represents a head-to-head comparison in a setting where surgery remains the standard of care. Full details are awaited.
- Unmeasured Confounders in Young TAVR: The Huang et al. Annals of Thoracic Surgery correspondence reinforces that non-randomized TAVR-vs-SAVR comparisons in younger adults are vulnerable to confounding — a critical point as both ACC/AHA and ESC guidelines agree that SAVR is preferred in patients under 65–70 years.
For broader context: the recently published meta-analysis by Khan et al. showing a 20% mortality reduction for TAVR vs. SAVR in lower-risk patients at 5 years (HR 0.80) continues to generate debate. As Kaul and others have noted, when intermediate-risk trials are excluded and only truly low-risk data are analyzed, the mortality difference attenuates. The ESC 2025 guidelines acknowledged this evidence in shifting the TAVI threshold to age ≥70, but the ACC/AHA position (age >80 or life expectancy <10 years for TAVI preference) remains more conservative. The truth likely lives in nuanced patient selection rather than age cutoffs — but age cutoffs are what guidelines must provide.
Device & Technology
In Silico Modeling of THV Oversizing and Elliptical Deployment
Boxwell et al. (Comput Methods Programs Biomed, 2026) present a validated computational framework modeling how THV oversizing and elliptical deployment affect leaflet mechanics, hemodynamics, and stent deformation. Key findings: oversizing reduced valve expansion at the supra-annular level (<90%), increased leaflet coaptation and pinwheeling, but paradoxically reduced peak leaflet stresses. However, oversizing also caused early mainstream flow separation, increasing oscillatory shear and viscous shear stress — both markers of thrombogenic risk. Elliptical deployment created heterogeneous stent deflections and variable leaflet stress distributions. The authors propose that more flexible THV stents could mitigate adverse effects and recommend post-TAVI balloon dilatation to optimize expansion. This work connects directly to the clinical concern about neosinus thrombosis reviewed by Chen et al. in JAHA today, and reinforces the lifetime management theme: sizing decisions at the index procedure have cascading consequences for durability and thrombosis risk.
TRICENTO G2: New First-in-Human Tricuspid Replacement System
A new first-in-man trial (NCT07536724) has been registered for the TRICENTO G2 transcatheter valve system for tricuspid regurgitation, sponsored by Medira GmbH, enrolling 10 patients. This adds another entry to an increasingly crowded tricuspid replacement field already populated by Edwards' EVOQUE, Medtronic's Intrepid (adapted), and various earlier-stage devices. The tricuspid replacement space is compelling — replacement offers a more complete solution for TR than repair — but the pacemaker rates, durability questions, and patient selection challenges remain unresolved.
Industry & Market
- Tissue Heart Valves Market Report: openPR.com published a tissue heart valve market analysis highlighting Edwards Lifesciences as a key player. While market reports like these tend toward boilerplate, the underlying trend is real: bioprosthetic tissue valves dominate the structural heart landscape, and the market is expanding as TAVR volumes grow and transcatheter mitral/tricuspid therapies mature.
- TriaGen Wealth Management Invests $4.55M in Edwards Lifesciences: MarketBeat reports institutional buying ahead of Q1 earnings. Institutional positioning before earnings is routine, but it signals confidence in Edwards' structural heart franchise despite the stock trading well below analyst targets.
Financial Analysis
The structural heart device sector faces a critical 48-hour window. Boston Scientific reports Q1 earnings tomorrow (April 22) and Edwards Lifesciences follows on Wednesday (April 23) — and both companies enter earnings season with their stocks under meaningful pressure. BSX has shed nearly 39% over six months, while EW has managed a modest 7% gain but remains 18% below analyst targets. The divergence is notable: Edwards' pure-play structural heart focus has provided relative stability, while Boston Scientific's broader portfolio has been caught in the broader medtech selloff.
For Edwards, the Q1 print will be the first major data point on whether the ESC 2025 guideline expansion (TAVI recommended at ≥70, TEER upgraded to Class I for ventricular SMR, tricuspid therapy at Class IIa) is translating into volume growth. Consensus expects $0.73 EPS on $1.60B revenue. Key metrics to watch: TAVR growth rate by geography (Europe should benefit from ESC alignment), TMTT segment performance (PASCAL and EVOQUE), and any commentary on competitive dynamics from the LANDMARK trial's positive Myval data. Edwards' forward P/E of 24.5x prices in significant growth, so any miss could be punished given the stock's recent recovery from January lows.
Boston Scientific's structural heart narrative is harder to isolate given its diversified portfolio, but WATCHMAN left atrial appendage closure and ACURATE neo2 TAVR franchise performance will be closely watched. The 5% single-day drop today suggests pre-earnings positioning or broader market anxiety. At a forward P/E of 15.6x, BSX is trading at a steep discount to its historical multiple, which either represents opportunity or a market re-rating of its growth trajectory.
The broader thesis: structural heart remains one of the highest-growth segments in medtech, driven by expanding indications (asymptomatic AS, tricuspid disease, atrial SMR) and guideline tailwinds. But the macro environment — tariff concerns, hospital capital expenditure uncertainty, and healthcare utilization patterns — creates near-term headwinds that may overshadow fundamental growth. Investors should also note that private players (JenaValve, Meril Life Sciences) continue to develop competitive TAVI platforms that could pressure pricing, particularly in emerging markets.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $81.44 (+$0.45, +0.56%)
- 6-Month Performance: +7.13%
- Market Cap: $47.3B
- P/E (trailing/forward): 44.99 / 24.53
- Beta: 0.94
- 52-Week Range: $69.21 – $87.89
- Analyst Consensus: Buy | Target $96.33 (range: $84–$110, 27 analysts) — 18.3% upside
- Next Earnings: April 23, 2026 | EPS est: $0.73 | Revenue est: $1.60B
Edwards enters earnings with modest momentum — up 0.56% today and 7.13% over six months, making it the best-performing name in our coverage universe. The stock has recovered from its January low of $69.21 but remains well below the $96.33 analyst consensus. Wednesday's report will be a referendum on whether ESC 2025 guideline expansion is driving procedure volumes. The SAPIEN 3 Ultra PMCF study (NCT04555967) remains active, and the new Chinese BAV TAVI registry (NCT07450196, 170 patients) signals Edwards' continued push into the BAV TAVI space despite both guidelines rating this as Class IIb. Key risk: the forward P/E of 24.5x assumes sustained high-single-digit TAVR growth — any deceleration would likely compress the multiple.
Medtronic (MDT)
- Close: $85.00 (-$1.19, -1.38%)
- 6-Month Performance: -9.92%
- Market Cap: $109.1B
- P/E (trailing/forward): 23.74 / 14.02
- Beta: 0.76
- 52-Week Range: $79.93 – $106.33
- Analyst Consensus: Buy | Target $109.08 (range: $91–$121, 25 analysts) — 28.3% upside
- Next Earnings: June 3, 2026 | EPS est: $1.56 | Revenue est: $9.62B
Medtronic continues its slide — down nearly 10% over six months and approaching its 52-week low of $79.93. The structural heart segment (Evolut TAVR, Intrepid TMVR) represents a small fraction of revenue but carries outsize strategic importance. The Evolut Low Risk trial (NCT02701283) long-term follow-up data will be critical for Medtronic's competitive positioning against Edwards' SAPIEN platform. The Intrepid TMVR Pivotal trial (NCT03242642, enrolling 1,056 patients) continues recruiting — this could be transformative if results support transcatheter mitral replacement as a viable therapy. At a forward P/E of 14.0x, Medtronic looks cheap relative to its medtech peers, but the discount reflects execution concerns across multiple business lines. The 28% gap to analyst targets is the widest in our coverage universe.
Abbott (ABT)
- Close: $96.00 (-$0.81, -0.84%)
- 6-Month Performance: -23.87%
- Market Cap: $166.8B
- P/E (trailing/forward): 26.89 / 15.84
- Beta: 0.78
- 52-Week Range: $93.92 – $139.06
- Analyst Consensus: Buy | Target $120.00 (range: $108–$143, 25 analysts) — 25.0% upside
- Next Earnings: July 16, 2026 | EPS est: $1.28 | Revenue est: $12.54B
Abbott has been hammered — down nearly 24% in six months and trading near its 52-week low. The structural heart franchise (MitraClip/TriClip) is a relative bright spot given the ESC 2025 upgrade of TEER for ventricular SMR to Class I and tricuspid TEER to Class IIa. The TRILUMINATE Pivotal trial (NCT03904147) is active and not recruiting, with longer-term data expected to further support the TriClip franchise. The REPAIR-MR trial (NCT04198870, MitraClip vs. surgery for primary MR) is also active — this could reshape the TEER-vs-surgery landscape for primary MR if results favor repair. Abbott's broader challenges (litigation headwinds, competitive pressures in diagnostics) are depressing the stock, but the structural heart pipeline remains compelling at these valuations.
Boston Scientific (BSX)
- Close: $60.99 (-$3.24, -5.04%)
- 6-Month Performance: -38.95%
- Market Cap: $90.6B
- P/E (trailing/forward): 31.44 / 15.64
- Beta: 0.78
- 52-Week Range: $60.59 – $109.50
- Analyst Consensus: Strong Buy | Target $96.66 (range: $69–$124, 32 analysts) — 58.5% upside
- Next Earnings: April 22, 2026 (TOMORROW) | EPS est: $0.79 | Revenue est: $5.17B
Boston Scientific dropped another 5% today and is down nearly 39% over six months — the sharpest decline in our coverage universe. The stock is trading at its 52-week low of $60.59, and tomorrow's earnings report is the most consequential near-term catalyst. The 58.5% gap between current price and analyst consensus ($96.66) is extraordinary — either analysts are dramatically wrong or the market is pricing in a scenario that hasn't materialized. BSX's structural heart exposure is more indirect (ACURATE neo2 TAVR in Europe, WATCHMAN LAAO), but the CLASP II TR trial (NCT04097145, PASCAL for TR) is a significant franchise bet with 870 patients enrolling. A strong Q1 print with reassuring guidance could catalyze a significant relief rally; a miss could test new lows.
Anteris Technologies (AVR.AX)
- Close: A$8.20 (-A$0.10, -1.20%)
- 6-Month Performance: -8.79%
- Market Cap: A$0.8B
- P/E (forward): -3.76 (pre-revenue)
- Beta: 0.55
- 52-Week Range: A$4.63 – A$9.79
- Analyst Target: A$13.00 (single analyst)
Anteris continues to trade in a range as it develops its DurAVR single-piece TAVR valve, designed for more physiologic hemodynamics and potentially improved durability through its unique single-piece design. As a pre-revenue company, Anteris is a speculative play on next-generation TAVR technology. The stock has recovered significantly from its 52-week low of A$4.63 but remains below the single analyst's A$13 target. Clinical data milestones will be the key catalysts.
Note: JenaValve Technology, J Valve Technology, and Meril Life Sciences are private companies without publicly traded equity.
Market Outlook
The structural heart sector enters earnings season at a crossroads. The fundamental story is the best it's ever been — ESC 2025 expanded indications across all three valve positions, asymptomatic AS intervention is moving mainstream, and tricuspid transcatheter therapy has arrived as a new treatment category. Yet the stocks tell a different story: three of five public names are down double digits over six months. The disconnect likely reflects macro headwinds (tariff uncertainty, healthcare utilization questions) rather than structural heart fundamentals. This week's BSX and EW earnings will either confirm the macro overhang or reveal underlying demand weakness. Investors with a 2–3 year horizon may find this an attractive entry point for the sector; those with shorter time horizons should wait for clarity from the earnings prints.
Clinical Trial Updates
Aortic Valve Trials
- NCT07539909 — Alternative Peripheral TAVI Accesses
- Status: Not Yet Recruiting
- Enrollment: 600
- Sponsor: Medical University of Silesia
- Phase: N/A
- A prospective evaluation of alternative access routes for TAVI — important as transfemoral access limitations remain a barrier for ~10–15% of TAVI candidates.
- ClinicalTrials.gov
- NCT07450196 — SAPIEN 3 TAVR for Type-0 Bicuspid AV in China
- Status: Not Yet Recruiting
- Enrollment: 170
- Sponsor: Fuwai Hospital / Chinese Academy of Medical Sciences
- A multicenter observational study of Edwards SAPIEN 3 in Type-0 BAV — the most challenging bicuspid morphology for TAVR. Both ACC/AHA and ESC rate BAV TAVI as Class IIb; this study could expand the evidence base.
- ClinicalTrials.gov
- NCT06816485 — INFLATE Study (Novel PTV Balloon for TAVI)
- Status: Recruiting
- Enrollment: 93
- Sponsor: Biosensors Europe SA
- Evaluating a novel percutaneous transcatheter valvuloplasty balloon for use during TAVI.
- ClinicalTrials.gov
- NCT05779787 — COMFORT Study (Coronary Re-engagement After Random Navigator Alignment)
- Status: Recruiting | Enrollment: 100 | Sponsor: Niguarda Hospital
- Evaluates commissural alignment vs. random alignment in TAVR — relevant to lifetime management and future coronary access, a key ESC 2025 emphasis.
- ClinicalTrials.gov
- NCT06000943 — Ischemic and Bleeding Risk Assessment After TAVR
- Status: Recruiting | Enrollment: 2,500 | Sponsor: Niguarda Hospital
- Stratifying post-TAVR patients by antithrombotic strategy (SAPT/DAPT/OAC) and surgical risk level.
- ClinicalTrials.gov
- NCT07532733 — Dexmedetomidine vs. Propofol/Remifentanil Sedation for TAVI
- Status: Not Yet Recruiting | Enrollment: 80 | Sponsor: Erasme University Hospital
- Head-to-head comparison of sedation strategies — relevant to TAVI efficiency initiatives.
- ClinicalTrials.gov
- NCT07236489 — Left Bundle Branch Area Stimulation vs. Conventional Pacing Post-TAVI
- Status: Recruiting | Enrollment: 266 | Sponsor: Nantes University Hospital
- Addresses one of TAVI's most persistent complications — conduction disturbance requiring pacemaker. Conduction-system pacing could mitigate the hemodynamic consequences of RV pacing.
- ClinicalTrials.gov
- NCT07519161 — Pharmacological Prevention of New-Onset AF After TAVR
- Status: Not Yet Recruiting | Enrollment: 198 | Sponsor: Shanghai East Hospital
- Metoprolol vs. amiodarone for NOAF prevention post-TAVR — NOAF affects 10–30% of TAVI patients and is associated with increased stroke and mortality.
- ClinicalTrials.gov
- NCT04555967 — SAPIEN 3 Ultra System PMCF
- Status: Active, Not Recruiting | Enrollment: 200 | Sponsor: Edwards Lifesciences
- ClinicalTrials.gov
Landmark Aortic Trials (Ongoing)
- [LANDMARK] NCT02701283 — Evolut Low Risk (Long-Term Follow-Up)
- Status: Active, Not Recruiting | Enrollment: 2,223 | Sponsor: Medtronic
- Long-term follow-up from the pivotal low-risk TAVR trial. Data beyond 5 years are critical for informing the SAVR-vs-TAVI debate in younger patients — the ESC 2025 shift to TAVI at ≥70 was partly based on available follow-up from this trial.
- ClinicalTrials.gov
Mitral Repair Trials
- [LANDMARK] NCT04198870 — REPAIR-MR (MitraClip vs. Surgery for Primary MR)
- Status: Active, Not Recruiting | Enrollment: 500 | Sponsor: Abbott Medical Devices
- This is the pivotal trial comparing TEER to surgery in primary MR — the result could fundamentally reshape the treatment algorithm. Both guidelines currently recommend surgery as first-line for primary MR; TEER is reserved for high-risk patients (Class IIa). If REPAIR-MR shows non-inferiority, the floodgates open.
- ClinicalTrials.gov
- [LANDMARK] NCT05051033 — PRIMATY (MitraClip vs. Medical Therapy for Secondary MR)
- Status: Recruiting | Enrollment: 450 | Sponsor: Annetine Gelijns
- Compares mitral valve repair (surgical) vs. TEER for secondary MR — addresses whether surgical repair has a role alongside TEER in the COAPT-era. Updated March 2026.
- ClinicalTrials.gov
- [LANDMARK] NCT03706833 — COAPT (Long-Term Follow-Up)
- Status: Active, Not Recruiting | Enrollment: 1,247 | Sponsor: Edwards Lifesciences
- Now includes PASCAL system alongside MitraClip. Extended follow-up from the trial that established TEER for ventricular SMR — the 5-year data drove the ESC 2025 Class I upgrade. Updated April 9, 2026.
- ClinicalTrials.gov
- NCT02924363 — MITRA-REVERSE (MitraClip Reverse Remodeling by CMR)
- Status: Completed | Enrollment: 54 | Sponsor: Dipan Shah
- CMR assessment of reverse cardiac remodeling after MitraClip — completed data should inform our understanding of structural recovery after TEER.
- ClinicalTrials.gov
- NCT07528781 — Novel 3D Echo Quantification of MR Volume
- Status: Recruiting | Enrollment: 200 | Sponsor: Germans Trias i Pujol Hospital
- AI-based analysis of 3D TEE data for MR volume quantification — better imaging could improve patient selection for both surgical and transcatheter MR therapy.
- ClinicalTrials.gov
Mitral Replacement Trials
- [LANDMARK] NCT03242642 — Intrepid TMVR Pivotal
- Status: Recruiting | Enrollment: 1,056 | Sponsor: Medtronic Cardiovascular
- The largest transcatheter mitral valve replacement trial, and the most important for establishing TMVR as a viable therapeutic category. Updated March 31, 2026. Completion of enrollment would be a watershed moment for the field.
- ClinicalTrials.gov
Tricuspid Repair Trials
- [LANDMARK] NCT03904147 — TRILUMINATE Pivotal (TriClip for TR)
- Status: Active, Not Recruiting | Enrollment: 572 | Sponsor: Abbott Medical Devices
- The trial that, along with Tri.Fr, established T-TEER as a Class IIa recommendation in ESC 2025. Longer-term data from this cohort will be critical for understanding durability — the 12-month data from today's Canadian study suggest real-world outcomes may diverge from trial results.
- ClinicalTrials.gov
- [LANDMARK] NCT04097145 — CLASP II TR (PASCAL for TR)
- Status: Recruiting | Enrollment: 870 | Sponsor: Edwards Lifesciences
- Edwards' pivotal trial for PASCAL in TR — the key competitor to Abbott's TriClip. Updated April 6, 2026. At 870 planned patients, this is a robust pivotal study.
- ClinicalTrials.gov
- NCT06479824 — TRAIPTA Early Feasibility Study (Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty)
- Status: SUSPENDED | Enrollment: 60 | Sponsor: NHLBI/Cook
- This novel annuloplasty approach is currently on hold — the reasons for suspension are not specified but worth monitoring.
- ClinicalTrials.gov
Tricuspid Replacement Trials
- [LANDMARK] NCT04482062 — TRISCEND II (Evoque Tricuspid Replacement)
- Status: Active, Not Recruiting | Enrollment: 864 | Sponsor: Edwards Lifesciences
- The pivotal trial that helped establish TTVR as a viable therapy — ESC 2025 cited these data in their Class IIa recommendation. Updated February 2026.
- ClinicalTrials.gov
- NCT07536724 — TRICENTO G2 First-in-Man (NEW)
- Status: Not Yet Recruiting | Enrollment: 10 | Sponsor: Medira GmbH
- First-in-human trial for a new transcatheter tricuspid valve replacement system. The tricuspid replacement space is expanding rapidly.
- ClinicalTrials.gov
- NCT06581471 — TRICURE EU Pivotal
- Status: Recruiting | Enrollment: 80 | Sponsor: TRiCares
- European pivotal study for another tricuspid replacement system — further populating an increasingly competitive landscape.
- ClinicalTrials.gov
Other Relevant Trials
- NCT05372627 — NHLBI-Emory Advanced Cardiac CT Reconstruction
- Status: Not Yet Recruiting | Enrollment: 1,000 | Sponsor: NHLBI
- Advanced CT reconstruction could improve pre-procedural planning for structural heart interventions.
- ClinicalTrials.gov
- NCT03152773 — MRI-Guided Heart Catheterization
- Status: SUSPENDED | Enrollment: 22 | Sponsor: NHLBI
- Novel imaging-guided catheterization approach — currently paused.
- ClinicalTrials.gov
Social & Conference Highlights
No major conference presentations or notable social media discussions identified today. The structural heart community's attention is directed toward this week's earnings reports and the ongoing assimilation of ESC 2025 guideline changes into clinical practice.
Looking Ahead: Tomorrow brings Boston Scientific Q1 earnings — watch for ACURATE neo2 and WATCHMAN commentary — and Wednesday is the main event with Edwards Lifesciences Q1, where TAVR volume trends and TMTT segment performance will set the narrative for structural heart in 2026. On the clinical side, the tricuspid space continues its rapid evolution: today's T-TEER vs. TTVR comparison and the ELASTA-T rescue technique both highlight that we're building the plane while flying it. The science needs to keep pace with the enthusiasm.
— E. Nolan Beckett | The Valve Wire